Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of CU-20401 in Healthy Chinese Subjects
NCT05173883Phase 1Completed
- Sponsor
- Cutia Therapeutics
- Start
- Dec 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of CU-20401 in localized adiposity (AL) (5 cohorts), sponsored by Cutia Therapeutics. Primary endpoint: Abdominal fat volume at Day 84. Started Dec 2021; status: completed.
02
Drugs
CU-20401
03
Conditions
localized adiposity (AL)
Beyond the preview
Go deeper on NCT05173883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05173883.